PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Results of Operations and Financial ConditionItem 2.02
99.1Press release announcing financial results for the second quarter ended June30, 2017, dated August9, 2017.
PIERIS PHARMACEUTICALS, INC. ExhibitEX-99.1 2 d440376dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30,…To view the full exhibit click here
About PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS)
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
